nach oben

Cardiovascular Toxicology

Erschienen in:

01.06.2007

Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries

verfasst von: Seppo W. Langer, Peter Buhl Jensen, Maxwell Sehested

Erschienen in: Cardiovascular Toxicology | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Dexrazoxane has been in clinical use for more than 25 years for prevention of cardiotoxicity in anthracycline based anticancer therapy. However, we discovered another property of the compound, i.e. the ability to prevent the devastating tissue necrosis after accidental extravasation of anthracyclines. The preclinical and clinical studies leading to the clinical implementation of Savene™ (dexrazoxane) as the first and only proven antidote in anthracycline extravasation are described in short.

Sehested, M., Jensen, P. B., Sorensen, B. S., Holm, B., Friche, E., & Dermant, E. J. F. (1993). Antagonistic effect of the cardioprotector (+)-1,2-Bis(3,5-Dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochemical Pharmacology, 46, 389–393.PubMedCrossRef

Langer, S. W., Sehested, M., & Jensen, P. B. (2000). Treatment of anthracycline extravasation with dexrazoxane. Clinical Cancer Research, 6, 3680–3686.PubMed

Langer, S. W., Sehested, M., & Jensen, P. B. (2001). Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Annual Oncology, 12, 405–410.CrossRef

Langer, S.W., Thougaard, A. V., & Sehested. M et al. (2006). Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemotherapy and Pharmacology, 57, 125–128.PubMedCrossRef

Langer, S. W., Sehested, M., & Jensen, P. B. et al. (2000). Dexrazoxane in anthracycline extravasation. Journal of Clinical Oncology, 18, 3064.PubMed

Bos, A. M., van der Graaf, W. T., & Willemse, P. H. (2001). A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane. Acta Oncology, 40, 541–542.CrossRef

Jensen, J. N., Lock-Andersen, J., & Langer, S. W. et al. (2003). Dexrazoxane–a promising antidote in the treatment of accidental extravasation of anthracyclines. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 37, 174–175.PubMedCrossRef

El Saghir, N., Otrock, Z., & Mufarrij, A. et al. (2004). Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. Lancet Oncology, 5, 320–321.PubMedCrossRef

Mouridsen, H. T., Langer, S.W., & Buter, J. et al. (2006). Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Annual Oncology, Dec 21.

10.

Mouridsen, H. T. et al. Treatment of anthracycline extravasation with Savene (dexrazoxane). Results from two prospective clinical multicenter studies. Annals of Oncology. (In press).

Titel: Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries
verfasst von: Seppo W. Langer
Peter Buhl Jensen
Maxwell Sehested
Publikationsdatum: 01.06.2007
Verlag: Humana Press Inc
Erschienen in: Cardiovascular Toxicology / Ausgabe 2/2007
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-007-0021-5

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries

Abstract

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

Role of anthracyclines in the era of targeted therapy

Anthracycline-induced phospholipase A2 inhibition

Novel antioxidants in anthracycline cardiotoxicity

Role of mtDNA lesions in anthracycline cardiotoxicity

Ongoing phase I and II studies of novel anthracyclines